Clinical trial
A Phase I, Multiple Center, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
NCT04818372 is registered in ClinicalTrials.gov with Keymed Biosciences Co.Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Multiple Center, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
- Lead sponsor
- Keymed Biosciences Co.Ltd
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- April 26, 2021
- Completion date
- April 30, 2023
- Enrollment
- 87 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.